© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 1, 30-37,
January 1, 2003
© 2003 Oxford University Press
ARTICLE |
Postmenopausal Hormone Therapy and Change in Mammographic Density
Affiliations of authors: G. A. Greendale, Division of Geriatric Medicine, David Geffen School of Medicine at UCLA, Los Angeles; B. A. Reboussin, S. Slone, C. Wasilauskas, Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC; M. C. Pike, G. Ursin, Department of Preventive Medicine/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles.
Correspondence to: Gail A. Greendale, M.D., Division of Geriatrics, UCLA School of Medicine, 10945 Le Conte Ave., Ste. 2339, Los Angeles, CA 900951687 (e-mail: ggreenda{at}mednet.ucla.edu).
Background: Mammographic density is an independent risk factor for breast cancer. Postmenopausal hormone use is associated with an increase in mammographic density, but the magnitude of the density increase is unknown. Methods: Baseline and 12-month mammograms were obtained for 571 (65%) of the 875 women, aged 4564 years, who were enrolled in the Postmenopausal Estrogen/Progestin Interventions Trial and randomly assigned to receive placebo, daily conjugated equine estrogens at 0.625 mg/day (CEE), daily CEE and medroxyprogesterone acetate (MPA) at 10 mg/day on days 112 (CEE+MPA-cyclic), daily CEE and MPA at 2.5 mg/day (CEE+MPA-continuous), or daily CEE and micronized progesterone (MP) at 200 mg/day on days 112 (CEE+MP). We analyzed digitized mammograms to determine the percentage of the left breast that was composed of dense tissue (i.e., mammographic percent density). Linear regression analysis was used to examine the effects of treatments on the change in mammographic percent density between baseline and 12 months, before and after adjustment for possible confounders. All statistical tests were two-sided. Results: The adjusted absolute mean changes in mammographic percent density over 12 months were 4.76% (95% confidence interval [CI] = 3.29% to 6.23%), 4.58% (95% CI = 3.19% to 5.97%), and 3.08% (95% CI = 1.65% to 4.51%) for women in the CEE+MPA-cyclic, CEE+MPA-continuous, and CEE-MP groups, respectively. Each of those absolute mean changes was statistically significantly different from the adjusted absolute mean change in mammographic percent density for women in the placebo group, which was -0.07% (95% CI = -1.50% to 1.38%). Conclusion: Greater mammographic density was associated with the use of estrogen/progestin combination therapy, regardless of how the progestin was given, but not with the use of estrogen only.
This article has been cited by other articles:
![]() |
R. L. Prentice, R. T. Chlebowski, M. L. Stefanick, J. E. Manson, M. Pettinger, S. L. Hendrix, F. A. Hubbell, C. Kooperberg, L. H. Kuller, D. S. Lane, et al. Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women Am. J. Epidemiol., May 15, 2008; 167(10): 1207 - 1216. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kerlikowske, D. S. M. Buist, R. Walker, and D. L. Miglioretti Response: Re: Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population J Natl Cancer Inst, April 16, 2008; 100(8): 599 - 599. [Full Text] [PDF] |
||||
![]() |
A. Kendall, H. Anderson, A. K. Dunbier, A. Mackay, T. Dexter, A. Urruticoechea, C. Harper-Wynne, and M. Dowsett Impact of Estrogen Deprivation on Gene Expression Profiles of Normal Postmenopausal Breast Tissue In vivo Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 855 - 863. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Chlebowski, G. Anderson, M. Pettinger, D. Lane, R. D. Langer, M. A. Gillian, B. W. Walsh, C. Chen, A. McTiernan, and for the Women's Health Initiative Investigators Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy Arch Intern Med, February 25, 2008; 168(4): 370 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lee, C. A. Haiman, H. Ma, D. Van Den Berg, L. Bernstein, and G. Ursin The Role of Established Breast Cancer Susceptibility Loci in Mammographic Density in Young Women Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 258 - 260. [Full Text] [PDF] |
||||
![]() |
C. Nagata, T. Matsubara, T. Hara, H. Fujita, Y. Nagao, S. Yamamoto, C. Shibuya, Y. Kashiki, and H. Shimizu Urinary 6-Sulfatoxymelatonin and Mammographic Density in Japanese Women Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2509 - 2512. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Wood, J. M. Hester, and J. M. Cline Mammary Gland Development in Early Pubertal Female Macaques Toxicol Pathol, October 1, 2007; 35(6): 793 - 803. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Fabian Low-Dose Tamoxifen for Combination Hormone Replacement Therapy Users J. Clin. Oncol., September 20, 2007; 25(27): 4162 - 4164. [Full Text] [PDF] |
||||
![]() |
K. Kerlikowske, D. L. Miglioretti, D. S. M. Buist, R. Walker, and P. A. Carney Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population J Natl Cancer Inst, September 5, 2007; 99(17): 1335 - 1339. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Tamimi, C. Byrne, G. A. Colditz, and S. E. Hankinson Endogenous Hormone Levels, Mammographic Density, and Subsequent Risk of Breast Cancer in Postmenopausal Women J Natl Cancer Inst, August 1, 2007; 99(15): 1178 - 1187. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Vachon, V. S. Pankratz, C. G. Scott, S. D. Maloney, K. Ghosh, K. R. Brandt, T. Milanese, M. J. Carston, and T. A. Sellers Longitudinal Trends in Mammographic Percent Density and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 921 - 928. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Reeves, G. L. Gierach, and F. Modugno Recreational Physical Activity and Mammographic Breast Density Characteristics Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 934 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J.B. van Duijnhoven, P. H.M. Peeters, R. M.L. Warren, S. A. Bingham, P. A.H. van Noord, E. M. Monninkhof, D. E. Grobbee, and C. H. van Gils Postmenopausal Hormone Therapy and Changes in Mammographic Density J. Clin. Oncol., April 10, 2007; 25(11): 1323 - 1328. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kerlikowske, L. Ichikawa, D. L. Miglioretti, D. S. M. Buist, P. M. Vacek, R. Smith-Bindman, B. Yankaskas, P. A. Carney, and R. Ballard-Barbash Longitudinal Measurement of Clinical Mammographic Breast Density to Improve Estimation of Breast Cancer Risk J Natl Cancer Inst, March 7, 2007; 99(5): 386 - 395. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Olson, C. X. Ma, L. L. Pelleymounter, D. J. Schaid, V. S. Pankratz, R. A. Vierkant, Z. S. Fredericksen, J. N. Ingle, Y. Wu, F. Couch, et al. A Comprehensive Examination of CYP19 Variation and Breast Density Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 623 - 625. [Full Text] [PDF] |
||||
![]() |
J. N. Weitzel, S. S. Buys, W. H. Sherman, A. M. Daniels, G. Ursin, J. R. Daniels, D. J. MacDonald, K. R. Blazer, M. C. Pike, and D. V. Spicer Reduced Mammographic Density with Use of a Gonadotropin-Releasing Hormone Agonist-Based Chemoprevention Regimen in BRCA1 Carriers Clin. Cancer Res., January 15, 2007; 13(2): 654 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Vachon, K. R. Brandt, K. Ghosh, C. G. Scott, S. D. Maloney, M. J. Carston, V. S. Pankratz, and T. A. Sellers Mammographic Breast Density as a General Marker of Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 43 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. F. Boyd, L. J. Martin, L. Sun, H. Guo, A. Chiarelli, G. Hislop, M. Yaffe, and S. Minkin Body Size, Mammographic Density, and Breast Cancer Risk. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2086 - 2092. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Chiarelli, V. A. Kirsh, N. S. Klar, R. Shumak, R. Jong, E. Fishell, M. J. Yaffe, and N. F. Boyd Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1856 - 1862. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Messina, W. McCaskill-Stevens, and J. W. Lampe Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst, September 20, 2006; 98(18): 1275 - 1284. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ursin and M. Pike Mammographic density, hormone therapy, and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1750 - 1750. [Full Text] [PDF] |
||||
![]() |
C. J. Crandall, A. Karlamangla, M.-H. Huang, G. Ursin, M. Guan, and G. A. Greendale Association of New-Onset Breast Discomfort With an Increase in Mammographic Density During Hormone Therapy Arch Intern Med, August 14, 2006; 166(15): 1578 - 1584. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Warren, J. Skinner, E. Sala, E. Denton, M. Dowsett, E. Folkerd, C. S. Healey, A. Dunning, D. Doody, B. Ponder, et al. Associations among Mammographic Density, Circulating Sex Hormones, and Polymorphisms in Sex Hormone Metabolism Genes in Postmenopausal Women. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1502 - 1508. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Palomares, J. R.B. Machia, C. D. Lehman, J. R. Daling, and A. McTiernan Mammographic density correlation with gail model breast cancer risk estimates and component risk factors. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1324 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. F. Boyd, L. J. Martin, Q. Li, L. Sun, A. M. Chiarelli, G. Hislop, M. J. Yaffe, and S. Minkin Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 961 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Maskarinec, I. Pagano, G. Lurie, and L. N. Kolonel A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 732 - 739. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J.B. van Duijnhoven, P. H.M. Peeters, R. M.L. Warren, S. A. Bingham, A. G. Uitterlinden, P. A.H. van Noord, E. M. Monninkhof, D. E. Grobbee, and C. H. van Gils Influence of Estrogen Receptor {alpha} and Progesterone Receptor Polymorphisms on the Effects of Hormone Therapy on Mammographic Density. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 462 - 467. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Haars, P. A.H. van Noord, C. H. van Gils, D. E. Grobbee, and P. H.M. Peeters Measurements of Breast Density: No Ratio for a Ratio Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2634 - 2640. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Tamimi, S. E. Hankinson, G. A. Colditz, and C. Byrne Endogenous Sex Hormone Levels and Mammographic Density among Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2641 - 2647. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Fenton, M. B. Barton, A. M. Geiger, L. J. Herrinton, S. J. Rolnick, E. L. Harris, W. E. Barlow, L. M. Reisch, S. W. Fletcher, and J. G. Elmore Screening Clinical Breast Examination: How Often Does It Miss Lethal Breast Cancer? J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 67 - 71. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Greendale, S. L. Palla, G. Ursin, G. A. Laughlin, C. Crandall, M. C. Pike, and B. A. Reboussin The Association of Endogenous Sex Steroids and Sex Steroid Binding Proteins with Mammographic Density: Results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study Am. J. Epidemiol., November 1, 2005; 162(9): 826 - 834. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Maskarinec, I. Pagano, G. Lurie, L. R. Wilkens, and L. N. Kolonel Mammographic Density and Breast Cancer Risk: The Multiethnic Cohort Study Am. J. Epidemiol., October 15, 2005; 162(8): 743 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. McTiernan, C. F. Martin, J. D. Peck, A. K. Aragaki, R. T. Chlebowski, E. D. Pisano, C. Y. Wang, R. L. Brunner, K. C. Johnson, J. E. Manson, et al. Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized Trial J Natl Cancer Inst, September 21, 2005; 97(18): 1366 - 1376. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Stuedal, I. T. Gram, Y. Bremnes, H. Adlercreutz, M. B. Veierod, and G. Ursin Plasma Levels of Enterolactone and Percentage Mammographic Density among Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2154 - 2159. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Dite, J. D. Wark, G. G. Giles, D. R. English, M. R.E. McCredie, and J. L. Hopper Is There Overlap Between the Genetic Determinants of Mammographic Density and Bone Mineral Density? Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2266 - 2268. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Berube, C. Diorio, B. Masse, N. Hebert-Croteau, C. Byrne, G. Cote, M. Pollak, M. Yaffe, and J. Brisson Vitamin D and Calcium Intakes from Food or Supplements and Mammographic Breast Density Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1653 - 1659. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Cerhan, T. A. Sellers, C. A. Janney, V. S. Pankratz, K. R. Brandt, and C. M. Vachon Prenatal and Perinatal Correlates of Adult Mammographic Breast Density Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1502 - 1508. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kerlikowske, J. Shepherd, J. Creasman, J. A. Tice, E. Ziv, and S. R. Cummings Are Breast Density and Bone Mineral Density Independent Risk Factors for Breast Cancer? J Natl Cancer Inst, March 2, 2005; 97(5): 368 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-S. Furberg, G. Jasienska, N. Bjurstam, P. A. Torjesen, A. Emaus, S. F. Lipson, P. T. Ellison, and I. Thune Metabolic and Hormonal Profiles: HDL Cholesterol as a Plausible Biomarker of Breast Cancer Risk. The Norwegian EBBA Study Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 33 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ziv, J. Tice, R. Smith-Bindman, J. Shepherd, S. Cummings, and K. Kerlikowske Mammographic Density and Estrogen Receptor Status of Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2090 - 2095. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Maskarinec, Y. Takata, A. A. Franke, A. E. Williams, and S. P. Murphy A 2-Year Soy Intervention in Premenopausal Women Does Not Change Mammographic Densities J. Nutr., November 1, 2004; 134(11): 3089 - 3094. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Fabian, B. F. Kimler, and M. S. Mayo Ductal Lavage for Early Detection--What Doesn't Come Out in the Wash J Natl Cancer Inst, October 20, 2004; 96(20): 1488 - 1489. [Full Text] [PDF] |
||||
![]() |
L. A. Habel, J. J. Dignam, S. R. Land, M. Salane, A. M. Capra, and T. B. Julian Mammographic Density and Breast Cancer After Ductal Carcinoma In Situ J Natl Cancer Inst, October 6, 2004; 96(19): 1467 - 1472. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ursin, S. L. Palla, B. A. Reboussin, S. Slone, C. Wasilauskas, M. C. Pike, and G. A. Greendale Post-Treatment Change in Serum Estrone Predicts Mammographic Percent Density Changes in Women Who Received Combination Estrogen and Progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial J. Clin. Oncol., July 15, 2004; 22(14): 2842 - 2848. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Frankenfeld, A. McTiernan, E. J. Aiello, W. K. Thomas, K. LaCroix, J. Schramm, S. M. Schwartz, V. L. Holt, and J. W. Lampe Mammographic Density in Relation to Daidzein-Metabolizing Phenotypes in Overweight, Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1156 - 1162. [Abstract] [Full Text] [PDF] |
||||
![]() |
ESHRE Capri Workshop Group Hormones and breast cancer Hum. Reprod. Update, July 1, 2004; 10(4): 281 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Decensi, B. Bonanni, L. Baglietto, A. Guerrieri-Gonzaga, F. Ramazzotto, H. Johansson, C. Robertson, I. Marinucci, F. Mariette, M. T. Sandri, et al. A Two-by-Two Factorial Trial Comparing Oral with Transdermal Estrogen Therapy and Fenretinide with Placebo on Breast Cancer Biomarkers Clin. Cancer Res., July 1, 2004; 10(13): 4389 - 4397. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cuzick, J. Warwick, E. Pinney, R. M. L. Warren, and S. W. Duffy Tamoxifen and Breast Density in Women at Increased Risk of Breast Cancer J Natl Cancer Inst, April 21, 2004; 96(8): 621 - 628. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. O. Lillie, L. Bernstein, S. A. Ingles, W. J. Gauderman, G. E. Rivas, V. Gagalang, T. Krontiris, and G. Ursin Polymorphism in the Androgen Receptor and Mammographic Density in Women Taking and Not Taking Estrogen and Progestin Therapy Cancer Res., February 15, 2004; 64(4): 1237 - 1241. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kerlikowske, D. L. Miglioretti, R. Ballard-Barbash, D. L. Weaver, D. S.M. Buist, W. E. Barlow, G. Cutter, B. M. Geller, B. Yankaskas, S. H. Taplin, et al. Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened Population J. Clin. Oncol., December 1, 2003; 21(23): 4314 - 4321. [Abstract] [Full Text] [PDF] |
||||










